ALDEYRA THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Debt Conversion, Converted Instrument, Amount of $170.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2016-03-30
- ALDEYRA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-12-31 was $0.00.
- ALDEYRA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-09-30 was $0.00.
- ALDEYRA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2014 was $170.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $170.00K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $170.00K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $170.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |